• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Koppel Adam bought $124,999,986 worth of shares (5,480,052 units at $22.81) (SEC Form 4)

    10/18/23 4:30:12 PM ET
    $CERE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CERE alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Koppel Adam

    (Last) (First) (Middle)
    C/O BAIN CAPITAL LIFE SCIENCES INVESTORS
    200 CLARENDON STREET

    (Street)
    BOSTON MA 02116

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Cerevel Therapeutics Holdings, Inc. [ CERE ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    10/16/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 10/16/2023 P 5,480,052(2) A $22.81 65,679,781 I See footnotes(1)
    Common Stock 3,282 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents shares of the Issuer's common stock held directly by BC Perception Holdings, LP ("BC Perception"). Adam Koppel is a Partner of Bain Capital Life Sciences Investors, LLC. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Dr. Koppel disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.
    2. On October 16, 2023, BC Perception purchased 5,480,052 shares of the Issuer's common stock at a price of $22.81 per share in an underwritten public offering.
    Remarks:
    /s/ Adam Koppel 10/18/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CERE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CERE

    DatePrice TargetRatingAnalyst
    12/8/2023$45.00Outperform → Market Perform
    TD Cowen
    11/20/2023$25.00Neutral
    JP Morgan
    9/28/2023$33.00Overweight
    Piper Sandler
    8/3/2023$36.00 → $31.00Buy → Neutral
    BofA Securities
    5/4/2023$30.00Equal Weight → Overweight
    Wells Fargo
    4/10/2023Outperform
    TD Cowen
    3/17/2023$40.00 → $29.00Overweight → Neutral
    JP Morgan
    3/16/2023$22.00Hold
    Berenberg
    More analyst ratings

    $CERE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AbbVie Completes Acquisition of Cerevel Therapeutics

      Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's diseaseEmraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophreniaCerevel is a strong strategic fit for AbbVie and has potential to meaningfully impact revenue into the next decadeAbbVie reaffirms previously issued 2024 full-year adjusted diluted EPS guidance range of $10.71-$10.91; reaffirms previously issued third-quarter adjusted diluted EPS guidance range of $2.92-$2.96NORTH CHICAGO, Ill., Aug. 1, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that it

      8/1/24 8:23:00 AM ET
      $ABBV
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • INVESTIGATION ANNOUNCEMENT: BFA Law Announces an Ongoing Investigation into the Merger between Cerevel Therapeutics and AbbVie for Unfair Process

      NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- If you invested in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation or contacting us below. Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie. Under the terms of the transaction, AbbVie will acquire all outstanding shares of Cerevel for $45.00 per share in cash. The transaction values Cerevel at a total equity value of approximately $8.7 billion. The boards of directors of both companies have approved the transaction. This transaction is expected to clo

      5/17/24 7:12:00 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease

      Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total "on" time without troublesome dyskinesia compared with placebo over 27 weeks Results demonstrate tavapadon's potential to provide the right balance of motor control, safety and tolerability for people living with Parkinson's disease Additional data from the trial will be presented at a future medical meeting; results from the tavapadon Phase 3 monotherapy trials (TEMPO-1 and TEMPO-2) are expected in the second half of 2024 CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unrav

      4/18/24 6:30:00 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CERE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Cerevel Therapeutics Holdings Inc.

      SC 13D/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)

      8/5/24 6:12:07 PM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cerevel Therapeutics Holdings Inc.

      SC 13D/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)

      8/5/24 4:30:55 PM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cerevel Therapeutics Holdings Inc. (Amendment)

      SC 13G/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)

      5/10/24 10:03:20 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CERE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cerevel Therapeutics downgraded by TD Cowen with a new price target

      TD Cowen downgraded Cerevel Therapeutics from Outperform to Market Perform and set a new price target of $45.00

      12/8/23 7:38:43 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan resumed coverage on Cerevel Therapeutics with a new price target

      JP Morgan resumed coverage of Cerevel Therapeutics with a rating of Neutral and set a new price target of $25.00

      11/20/23 7:22:24 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Cerevel Therapeutics with a new price target

      Piper Sandler initiated coverage of Cerevel Therapeutics with a rating of Overweight and set a new price target of $33.00

      9/28/23 8:09:00 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CERE
    Leadership Updates

    Live Leadership Updates

    See more
    • Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer

      Mr. Burgess will be responsible for leading Cerevel's business development and quality teams Mr. Burgess to join Cerevel effective June 20, 2023 CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Paul Burgess as chief business development and strategic operations officer, effective June 20, 2023. "I am so pleased to welcome Paul to Cerevel as our chief business development and strategic operations officer, with his proven track record of success in the biotech and pharmaceutical industry," said Ron Renaud, president and chie

      6/15/23 6:30:00 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer

      Susan Altschuller, Ph.D. brings financial management, investor relations, and business planning experience from leading pharmaceutical and biotechnology companies to Cerevel Dr. Altschuller to become CFO effective May 15, 2023 CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Susan Altschuller, Ph.D. as chief financial officer (CFO), effective May 15, 2023. "We are excited to welcome Susan to Cerevel, as she brings a breadth of experience leading biopharmaceutical companies by leveraging her strategic understanding, f

      5/10/23 6:30:00 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cerevel Therapeutics Announces the Appointment of Scott M. Akamine as Chief Legal Officer

      CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Scott M. Akamine as chief legal officer, effective May 24, 2021. An accomplished legal executive, Mr. Akamine brings significant healthcare and biopharmaceutical experience to the role. He joins Cerevel from AEON Biopharma, Inc., a privately-held biopharmaceutical company, where he served as general counsel and corporate secretary, overseeing legal and certain administrative functions, including business development, corporate governance, intellectual property, and compliance. 

      5/4/21 7:00:00 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CERE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CERE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Koppel Adam bought $124,999,986 worth of shares (5,480,052 units at $22.81) (SEC Form 4)

      4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)

      10/18/23 4:30:12 PM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gordon Christopher R bought $124,999,986 worth of shares (5,480,052 units at $22.81) (SEC Form 4)

      4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)

      10/18/23 4:30:16 PM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bain Capital Investors Llc bought $124,999,986 worth of shares (5,480,052 units at $22.81) (SEC Form 4)

      4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)

      10/18/23 4:30:09 PM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Former 10% Owner Pfizer Inc closing all direct ownership in the company (SEC Form 4)

      4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)

      8/5/24 6:25:19 PM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bain Capital Investors Llc returned 65,679,781 shares to the company (SEC Form 4)

      4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)

      8/5/24 4:52:52 PM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Gordon Christopher R returned 65,693,524 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)

      8/5/24 4:51:04 PM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CERE
    Financials

    Live finance-specific insights

    See more
    • AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline

      Proposed acquisition adds robust pipeline of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remainCerevel's clinical-stage pipeline complements AbbVie's current on-market portfolio and emerging neuroscience pipelineEmraclidine has the potential to transform the standard of care in schizophrenia and other psychiatric conditionsTransaction valued at $45.00 per share in cash, for a total equity value of approximately $8.7 billionAbbVie to hold an investor conference call tomorrow, December 7, at 8:00 a.m. CTNORTH CHICAGO, Ill. and CAMBRIDGE, Mass., Dec. 6, 2023 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) and Cerevel Therapeutics (N

      12/6/23 4:30:00 PM ET
      $ABBV
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023

      CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2023 financial results and business updates on Wednesday, November 1, 2023, before the U.S. financial markets open. Management will host a conference call to discuss third quarter financial results and business updates on Wednesday, November 1 at 8:00 a.m. ET. To access the call, please register at this link. Once registered, you will receive the dial-in information and a unique PIN number. A live webcast of the call, along with supporting slides, will be availabl

      10/13/23 6:30:00 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

      Three new executives added to leadership team: Ron Renaud, Susan Altschuller, Paul Burgess Emraclidine EMPOWER data now expected second half 2024 Darigabat ADAPT trial in panic disorder initiated Cash, cash equivalents, and marketable securities of $825.1 million as of June 30, 2023, expected to support a data-rich 2024 and fund operations into 2025 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) --  Cerevel Therapeutics, (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the second quarter ended June 30, 2023 and provided key pipeline and business updat

      8/2/23 6:30:00 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CERE
    SEC Filings

    See more
    • SEC Form 15-12G filed by Cerevel Therapeutics Holdings Inc.

      15-12G - Cerevel Therapeutics Holdings, Inc. (0001805387) (Filer)

      8/12/24 7:30:56 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.

      EFFECT - Cerevel Therapeutics Holdings, Inc. (0001805387) (Filer)

      8/6/24 12:15:03 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.

      EFFECT - Cerevel Therapeutics Holdings, Inc. (0001805387) (Filer)

      8/6/24 12:15:15 AM ET
      $CERE
      Biotechnology: Pharmaceutical Preparations
      Health Care